Study to Evaluate Pharmacokinetic and Bioavailability of Envarsus® vs. Advagraf® in Liver Transplant Recipients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Single centre, open-label, randomized, controlled, cross over study to evaluate the pharmacokinetic and bioavailability of Envarsus® in comparison to Advagraf® in de novo liver transplant recipients
Condition or disease
Drug: Treatment 2 weeks Envarsus followed by 2 weeks AdvagrafDrug: Treatment 2 weeks Advagraf followed by 2 weeks Envarsus
Using an open-label, randomized, controlled, 2-period cross-over design, two treatments (Envarsus® and Advagraf®) will be compared (with regard to PK profile and bioavailability) after administration of IMP to 20 de novo transplanted recipients. The patients will be randomly assigned to one of the two treatments as treatment period 1 and afterwards switched to treatment period 2 (Group 1: Envarsus® - Advagraf®; Group 2: Advagraf® - Envarsus®).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Ability to understand the patient information and to personally sign and date the informed consent to participate in the clinical trial, before completing any clinical trial related procedures.
Male or female recipients ≥ 18 years of a liver graft from a deceased or living donor
The patient must receive a twice daily Tacrolimus based immunosuppression treatment.
Females of child-bearing potential who agree to comply with any applicable contraceptive requirements of the protocol or females who are permanently sterilized (at least 6 weeks post sterilization).
Non-pregnant, non-lactating female.
Recipients of a first or re-liver transplant in the last 30 days
The patient is co-operative and available for the entire clinical trial.
Patients with a known hypersensitivity to any of the drugs used in the study.
Patients who are not able to take oral medication at the time point of randomization.
Recipients of combined organ transplants.
Patients who are recipients of AB0 incompatible transplant grafts.
Currently participation in a clinical trial and any IMP intake within the last four weeks.
Patients who use drugs known to strongly interact with the cytochrome P-450 3A4 pathway and therefore influence the tacrolimus blood level are not allowed during Envarsus®/Advagraf® treatment period.
Patient with renal impairment with need of dialysis treatment at the time point of randomization.